Skip to main content
Mitarbeiter-/PI-Porträt Michael Stumvoll
Helmholtz Munich | ©Swen Reichhold

Prof. Dr. med. Michael Stumvoll

Clinical Programme Director, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) and Professor of Medicine/Director of Medical Department 3 (Endocrinology, Nephrology, Rheumatology), University of Leipzig Medical Centre


Prof. Dr. med. Michael Stumvoll

Clinical Programme Director, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) and Professor of Medicine/Director of Medical Department 3 (Endocrinology, Nephrology, Rheumatology), University of Leipzig Medical Centre

Academic Career

Michael Stumvoll is the Founding Director of the HI-MAG. Together with Matthias Tschöp, they developed the concept to enhance the cooperation between Helmholtz Munich, a world leader in basic research of metabolic diseases, including obesity and type 2 diabetes, and Leipzig University Medical Centre, a worldrenowned clinical research institution in metabolic medicine. The HI-MAG has been established to research new treatment options for obesity and its co-morbidities through clinical trials following the bedside to bench to bedside approach. To achieve this objective, Michael, as the Clinical Programme Director, ensures patient access for HI-MAG, allowing it to conduct clinical studies at the University of Leipzig Medical Centre, primarily with research questions in metabolic diseases. He is overseeing all clinical studies and projects within the clinical trial unit of HI-MAG. Together with the clinician scientists and the three HI-MAG professors, Michael is developing new concepts for translational medicine in metabolism, altering energy metabolism, improving the microbiome, understanding the role of the brain in eating behaviour.


Michael studied Medicine at the Ludwig Maximilian University of Munich and obtained his MD under the supervision of Prof. Dr. E. Ernst in 1990. After spending two years  in NHS hospitals in the UK as Medical House Officer, Michael continued his medical training at the University Medical Centre Tübingen, Germany, where he completed his residency in internal medicine and endocrinology. During this time, he went abroad several times, including stays at Scripps Research, La Jolla, USA and the University of Rochester, New York, USA. Upon completion of his “Habilitation” in 2001 at the Unviersity of Tübingen, Michael went to the National Institutes of Health, where he worked as an Adjunct Investigator in the Clinical Diabetes and Nutrition Section, Phoenix, Arizona, USA. In 2004, Michael was appointed professorship of internal medicine/endocrinology at the University of Leipzig and became the director of the Divisions of Endocrinology, Nephrology and Rheumatology at the Leipzig University Medical Center. Since then, Michael has significantly strengthened and advanced Leipzig’s expertise in metabolic medicine, specifically by establishing the DFG research group “Atherobesity” in 2006 and the IFB “AdiposityDiseases” in 2011 from which HI-MAG evolved.

Michael’s reasearch focuses on endocrinonolgy and metabolism, genetics and heredity, nutrition and dietetics, as well as biochemistry and molecular biology.

Research Areas and Expertise

Regulation of glucose metabolism, the pathogenesis and treatment of Type-2-Diabetes, the kinetics of insulin secretion, measuring and understanding insulin resistance, mathematical modelling of the oral glucose tolerance test, the genetics of diabetes and obesity, neuroendocrine control of appetite and adipose tissue as a secretory organ and recently the role of the microbiome in diabetes and obesity

Important Career Steps

since 2019

Clinical Programme Director of the Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig 


Dean of the Faculty of Medicine, Leipzig University


Medical Chairmann (Vorstand), University Mecical Center Leipzig


Since 2018

Founding Director of the Helmholtz-Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Leipzig


Dean of the Faculty of Medicine, Leipzig University

Since 2004

Professor of Medicine (C4)

Chief of Endocrinology, Diabetology, Nephrology

Medical Director, Divisions of Endocrinology, Nephrology & Rheumatology, University Medical Centre Leipzig


Adjunct Investigator, Clinical Diabetes and Nutrition Section, National Institutes of Health, Phoenix, USA (Dr. C. Bogardus) 

Honors and Awards

  • Member of
    the Saxonian Academy of Science
    since 2017

  • Werner-Creutzfeld Award
    German Diabetes Association (DDG)

  • Minkowski Award
    European Association for
    the Study of Diabetes (EASD)

  • Heisenberg Fellowship
    Deutsche Forschungsgemeinschaft (DFG)

  • Ferdinand-Bertram-Award
    Deutsche Forschungsgemeinschaft (DFG)

Variante: Gold Star Awards Luxury Background
suppa -

Selected Publications

See all

2021 Nature

S. K. Forslund, R. Chakaroun, M. Zimmermann-Kogadeeva, L. Markó, J. Aron-Wisnewsky, T. Nielsen, L. Moitinho-Silva, T. S. B. Schmidt, G. Falony, S. Vieira-Silva, S. Adriouch, R. J. Alves, K. Assmann, J.-P. Bastard, T. Birkner, R. Caesar, J. Chilloux, L. P. Coelho, L. Fezeu, N. Galleron, G. Helft, R. Isnard, B. Ji, M. Kuhn, E. Le Chatelier, A. Myridakis, L. Olsson, N. Pons, E. Prifti, B. Quinquis, H. Roume, J.-E. Salem, N. Sokolovska, V. Tremaroli, M. Valles-Colomer, Chr. Lewinter, N. B. Søndertoft, H. Krogh Pedersen, T. H. Hansen, MetaCardis Consortium, J. P. Gøtze, L. Køber, H. Vestergaard, T. Hansen, J.-D. Zucker, S. Hercberg, J.-M. Oppert, I. Letunic, J. Nielsen, F. Bäckhed, S. D. Ehrlich, M.-E. Dumas, J. Raes, O. Pedersen, K. Clément, M. Stumvoll, P. Bork

Combinatorial, Additive and Dose-Dependent Drug-Microbiome Associations

2008 New England Journal of Medicine

I. Shai, D. Schwarzfuchs, Y. Henkin, D. R. Shahar, Sh. Witkow, I. Greenberg, R. Golan, D. Fraser, A. Bolotin, H. Vardi, O. Tangi-Rozental, R. Zuk-Ramot, B. Sarusi, D. Brickner, Z. Schwartz, E. Sheiner, R. Marko, E. Katorza, J. Thiery, G. M. Fiedler, M. Blüher, M. Stumvoll, M. J. Stampfer, Dietary Intervention Randomized Controlled Trial (DIRECT) Group

Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet